Explore how biomarkers can predict BCG failure in high-risk bladder cancer, aiding in personalized treatment strategies.

The FDA has approved atezolizumab combined with chemotherapy for treating stage III dMMR colon cancer, enhancing post-surgery treatment options.

A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...

Learn how intelligent medical records enhance patient care, streamline workflows, and improve healthcare outcomes through ...

Explore a comparative study on ESR1 mutation testing using dPCR and NGS. Understand the strengths and applications of each ...

Explore the FDA fast track oncology drugs granted in September 2026, advancing treatments for various cancer types.

When it comes to treatment decisions for patients with EGFR-mutated non-small cell lung cancer, “the most important conversations are not the data-driven ones, they are the relational ones,” patient ...

At WCLC 2026, three thoracic oncologists discuss first-line regimen selection, subcutaneous dosing, dermatologic prophylaxis, and dose modifications in EGFR-mutant NSCLC. Subcutaneous amivantamab has ...

Community oncology practices can point to advantages such as care closer to home, greater affordability, and a more ...